Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate updates announced on November 5, 2026.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and corporate updates announced on November 5, 2026
- Full results and operating details provided in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $24.7M, or $0.40 per share, improved from $27.9M, or $0.47, despite collaboration revenue falling to $4.0M from $13.4M
- Cash, equivalents and marketable securities $132.1M at September 30, funding planned operations into Q2 2028
- VY7523 tau PET efficacy data remains scheduled for Q4 2026, a key Alzheimer’s clinical catalyst
- VY1706 first-patient dosing expected within months, with initial safety data anticipated in Q1 2027
- Neurocrine-partnered Friedreich’s ataxia program expected to enter Phase 1 in coming months, with initial patient data anticipated in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.